Lipid Emulsion Use in Pediatric Patients Requiring Long-Term Parenteral Nutrition.
IFALD
fish oil
intestinal failure
intravenous lipid emulsions
nutrition
parenteral nutrition
pediatrics
soybean oil
Journal
JPEN. Journal of parenteral and enteral nutrition
ISSN: 1941-2444
Titre abrégé: JPEN J Parenter Enteral Nutr
Pays: United States
ID NLM: 7804134
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
received:
27
08
2019
revised:
20
11
2019
accepted:
22
11
2019
entrez:
13
2
2020
pubmed:
13
2
2020
medline:
4
3
2021
Statut:
ppublish
Résumé
The ability to deliver nutrients via parenteral nutrition (PN) has markedly improved the prognosis of infants and children with intestinal failure. Technical refinements and advances in knowledge have led to the development of highly sophisticated PN solutions that are tailored to meet the needs of pediatric patients. However, children who require long-term PN have an increased risk of complications such as catheter-related sepsis, liver disease, and bone disease. Although the pathogenesis of intestinal failure associated liver disease (IFALD) is multifactorial, studies have identified a possible link between the dose of lipid emulsions based on soybean oil and cholestasis, shown to occur with a significantly higher frequency in patients receiving >1 g lipids/kg/d. Potential contributing factors include oxidative stress, high ω-6 polyunsaturated fatty acid (PUFA) and phytosterol content, and relatively low α-tocopherol levels. Lipid emulsions containing fish oil offer potential advantages compared with traditional emulsions with a high soybean oil content, such as decreased ω-6 and increased ω-3 PUFA concentrations, high concentrations of α-tocopherol, and reduced phytosterol content. Studies in PN-dependent children at risk for IFALD have shown that lipid emulsions containing fish oil reduce the risk of cholestasis and improve biochemical measures of hepatobiliary function compared with pure soybean oil emulsions. This review summarizes evidence regarding the role of lipid emulsions in the management of pediatric patients with intestinal failure requiring long-term PN, with a particular focus on the prevention and treatment of IFALD.
Substances chimiques
Emulsions
0
Fat Emulsions, Intravenous
0
Fish Oils
0
Parenteral Nutrition Solutions
0
Soybean Oil
8001-22-7
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
S55-S67Informations de copyright
© 2020 American Society for Parenteral and Enteral Nutrition.
Références
Lapillonne A, Fidler Mis N, Goulet O, van den Akker C, Wu J, Koletzko B; the ESPGHAN/ ESPEN/ESPR/CSPEN working group on pediatric parenteral nutrition. ESPGHAN/ESPEN/ESPR/CSPEN Guidelines on pediatric parenteral nutrition: lipids. Clin Nutr. 2018;37(6 Pt B):2324-2336.
Klek S. Omega-3 fatty acids in modern parenteral nutrition: a review of the current evidence. J Clin Med. 2016;5(3):E34.
Deshpande GC, Cai W. Use of lipids in neonates requiring parenteral nutrition. J Parenter Enteral Nutr. 2020;44(Suppl S1):S45-S54.
Goulet O, Olieman J, Ksiazyk J, et al. Neonatal short bowel syndrome as a model of intestinal failure: physiological background for enteral feeding. Clin Nutr. 2013;32(2):162-171.
Hill S, Ksiazyk J, Prell C, Tabbers M; the ESPGHAN/ESPEN/ESPR/CSPEN working group on pediatric parenteral nutrition. ESPGHAN/ESPEN/ESPR/CSPEN guidelines on pediatric parenteral nutrition: home parenteral nutrition. Clin Nutr. 2018;(6 Pt B):37:2401-2408.
Goulet O. Intestinal failure in children. Transplant Proc. 1998;30(6):2523-2525.
Goulet O, Ruemmele F, Lacaille F, Colomb V. Irreversible intestinal failure. J Pediatr Gastroenterol Nutr. 2004;38(3):250-269.
Goulet O, Ruemmele F. Causes and management of intestinal failure in children. Gastroenterology. 2006;130(2 suppl 1):S16-S28.
Goulet O, Joly F, Corriol O, Colomb-Jung V. Some new insights in intestinal failure-associated liver disease. Curr Opin Organ Transplant. 2009;14(3):256-261.
Goulet OJ. Intestinal failure-associated liver disease and the use of fish oil-based lipid emulsions. In: Calder PC, Waitzberg DL, Koletzko B, eds. Intravenous Lipid Emulsions. Basel, Switzerland: Karger; 2015;90-114. World Rev Nutr Diet; vol 112.
Hartman C, Shamir R, Simchowitz V, Lohner S, Cai W, Decsi T; the ESPGHAN/ESPEN/ ESPR/CSPEN working group on pediatric parenteral nutrition. ESPGHAN/ESPEN/ESPR/CSPEN guidelines on pediatric parenteral nutrition: complications. Clin Nutr. 2018;37(6 Pt B):2418-2429.
Lambe C, Poisson C, Talbotec C, Goulet O. Strategies to reduce catheter-related bloodstream infections in pediatric patients receiving home parenteral nutrition: the efficacy of taurolidine-citrate prophylactic-locking. J Parenter Enteral Nutr. 2018;42(6):1017-1025.
Lacaille F, Gupte G, Colomb V, et al. Intestinal failure-associated liver disease: a position paper of the ESPGHAN Working Group of Intestinal Failure and Intestinal Transplantation. J Pediatr Gastroenterol Nutr. 2015;60(2):272-283.
Martindale RG, Berlana D, Boullata JI, et al. Summary of proceedings and consensus statements from the international summit ‘Lipids in Parenteral Nutrition’. J Parenter Enteral Nutr. 2020;44(Suppl S1):S7-S20.
Hojsak I, Colomb V, Braegger C, et al. ESPGHAN Committee on nutrition position paper. Intravenous lipid emulsions and risk of hepatotoxicity in infants and children: a systematic review and meta-analysis. J Pediatr Gastroenterol Nutr. 2016;62(5):776-792.
Lauriti G, Zani A, Aufieri R, et al. Incidence, prevention, and treatment of parenteral nutrition-associated cholestasis and intestinal failure-associated liver disease in infants and children: a systematic review. J Parenter Enteral Nutr. 2014;38(1):70-85.
Klein CJ, Revenis M, Kusenda C, et al. Parenteral nutrition-associated conjugated hyper-bilirubinemia in hospitalized infants. J Am Diet Assoc. 2010;110(11):1684-1695.
Kaufman SS. Prevention of parenteral nutrition-associated liver disease in children. Pediatr Transplant. 2002;6(1):37-42.
Nightingale JM. Hepatobiliary, renal, and bone complications of intestinal failure. Best Pract Res Clin Gastroenterol. 2003;17(6):907-929.
Demehri FR, Barrett M, Ralls MW, Miyasaka EA, Feng Y, Teitelbaum DH. Intestinal epithelial cell apoptosis and loss of barrier function in the setting of altered microbiota with enteral nutrient deprivation. Front Cell Infect Microbiol. 2013;3:105.
Pierro A, van Saene HK, Donnell SC, et al. Microbial translocation in neonates and infants receiving long-term parenteral nutrition. Arch Surg. 1996;131(2):176-179.
Wales PW, de Silva N, Kim JH, Lecce L, Sandhu A, Moore AM. Neonatal short bowel syndrome: a cohort study. J Pediatr Surg. 2005;40(5):755-762.
Squires RH, Duggan C, Teitelbaum DH, et al; Pediatric Intestinal Failure Consortium. Natural history of pediatric intestinal failure: initial report from the Pediatric Intestinal Failure Consortium. J Pediatr. 2012;16(4):723-728.
Hukkinen M, Mutanen A, Pakarinen MP. Small bowel dilation in children with short bowel syndrome is associated with mucosal damage, bowel-derived bloodstream infections, and hepatic injury. Surgery. 2017;162(3):670-679.
Goulet O, Abi Nader E, Pigneur B, Lambe C. Short bowel syndrome as the leading cause of intestinal failure in early life: some insights into the management. Pediatr Gastroenterol Hepatol Nutr. 2019;22(4):303-329.
Kosters A, Karpen SJ. The role of inflammation in cholestasis: clinical and basic aspects. Semin Liver Dis. 2010;30(2):186-194.
Lee WS, Sokol RJ. Intestinal microbiota, lipids, and the pathogenesis of intestinal failure-associated liver disease. J Pediatr. 2015;167(3):519-526.
Wagner M, Zollner G, Trauner M. Nuclear receptor regulation of the adaptive response of bile acid transporters in cholestasis. Semin Liver Dis. 2010;30(2):160-177.
Trauner M, Boyer JL. Cholestatic syndromes. Curr Opin Gastroenterol. 2003;19(3):216-231.
Geier A, Fickert P, Trauner M. Mechanisms of disease: mechanisms and clinical implications of cholestasis in sepsis. Nat Clin Pract Gastroenterol Hepatol. 2006;3(10):574-585.
Aprahamian CJ, Chen M, Yang Y, Lorenz RG, Harmon CM. Two-hit rat model of short bowel syndrome and sepsis: independent of total parenteral nutrition, short bowel syndrome is proinflammatory and injurious to the liver. J Pediatr Surg. 2007;42(6):992-997.
Wagner M, Zollner G, Trauner M. New molecular insights into the mechanisms of cholestasis. J Hepatol. 2009;51(3):565-580.
Mulder J, Karpen SJ, Tietge UJ, Kuipers F. Nuclear receptors: mediators and modifiers of inflammation-induced cholestasis. Front Biosc. 2009;14:2599-2630.
Soroka CJ, Ballatori N, Boyer JL. Organic solute transporter, OSTot-OSTI3: its role in bile acid transport and cholestasis. Semin Liver Dis. 2010;30(2):176-183.
Hermans D, Talbotec C, Lacaille F, et al. Early central catheter infections may contribute to hepatic fibrosis in children receiving long-term parenteral nutrition. J Pediatr Gastroenterol Nutr. 2007;44(4):459-463.
Wales PW, Aleen N, Worthington P, Compher C, Tietelbaum D. A.S.P.E.N. clinical guidelines: support of pediatric patients with intestinal failure at risk of parenteral nutrition-associated liver disease. J Parenter Enteral Nutr. 2014;38(5):538-557.
Colomb V, Dabbas-Tyan M, Taupin P, et al. Long-term outcome of children receiving home parenteral nutrition: a 20-year single-center experience in 302 patients. J Pediatr Gastroenterol Nutr. 2007;44(3):347-353.
Gillanders L, Angstmann K, Ball P, et al. A prospective study of catheter-related complications in HPN patients. Clin Nutr. 2012;31(1):30-34.
Hojsak I, Strizić H, Miŝak Z, et al. Central venous catheter related sepsis in children on parenteral nutrition: a 21-year single center experience. Clin Nutr. 2012;31(5):672-675.
Wiskin AE, Cole C, Owens DR, Morgan M, Burge DM, Beattie RM. Ten-year experience of home parenteral nutrition in a single centre. Acta Paediatr. 2012;101(5):524-527.
Abi Nader E, Lambe C, Talbotec C, et al. Outcome of home parenteral nutrition in 251 children over a 14-y period: report of a single center. Am J Clin Nutr. 2016;103(5):1327-1336.
Beath SV, Booth IW, Murphy MS. Nutritional care in candidates for small bowel transplantation. Arch Dis Child. 1995; 73(4):348-350.
Colomb V, Fabeiro M, Dabbas M, et al. Central venous catheter-related infections in children on long-term home parenteral nutrition: incidence and risk factors. Clin Nutr. 2000;19(5):355-359.
Carter BA, Karpen SJ. Intestinal failure-associated liver disease: management and treatment strategies past, present, and future. Semin Liver Dis. 2007;27(3):251-258.
Kawano T, Kaji T, Onishi S, et al. Efficacy of ethanol locks to reduce the incidence of catheter-related bloodstream infections for home parenteral nutrition pediatric patients: comparison of therapeutic treatment with prophylactic treatment. Pediatr Surg Int. 2016;32(9):863-867.
Kolaček S, Puntis JWL, Hojsak I; ESPGHAN/ESPEN/ESPR/CSPEN working group on pediatric parenteral nutrition. ESPGHAN/ESPEN/ESPR/CSPEN guidelines on pediatric parenteral nutrition: venous access. Clin Nutr. 2018;37(6 Pt B):2379-2391.
Goulet O, Girot R, Maier-Redelsperger M, et al. Hematologic disorders following prolonged use of intravenous fat in children. J Parenter Enteral Nutr. 1986;10(3):284-288.
Buchman AL, Iyer K, Fryer J. Parenteral nutrition-associated liver disease and the role of isolated intestine and intestine/liver transplantation. Hepatology. 2006;43(1):9-19.
Sondheimer JM, Asturias E, Cadnapaphornchai M. Infection and cholestasis in neonates with intestinal resection and long term parenteral nutrition. J Pediatr Gastroenterol Nutr. 1998;6(2):131-137.
Bach AC, Frey A, Lutz O. Clinical and experimental effects of medium-chain-triglyceride-based fat emulsions-a review. Clin Nutr. 1989;8(5):223-235.
Cavicchi M, Beau P, Crenn P, et al. Prevalence of liver disease and contributing factors in patients receiving home parenteral nutrition for permanent intestinal failure. Ann Intern Med. 2000;132(7):525-532.
Colomb V, Jobert-Giraud A, Lacaille F, et al. Role of lipid emulsions in cholestasis associated with long-term parenteral nutrition in children. J Parenter Enteral Nutr. 2000;24(6):345-350.
Wanten G, Beunk J, Naber A, Swinkels D. Tocopherol isoforms in parenteral lipid emulsions and neutrophil activation. Clin Nutr. 2002;21(5):417-422.
Dupont IE. Peroxidation of lipid emulsions: effects of changes in fatty acid pattern and alpha-tocopherol content on the sensitivity to peroxidative damage. Clin Nutr. 1999;18(2):113-116.
Vanek VW, Seidner DL, Allen P, et al. A.S.P.E.N. position paper: clinical role for alternative intravenous fat emulsions. Nutr Clin Pract. 2012;27(2):150-192.
Wanten G, Calder PC. Immune modulation by parenteral lipid emulsions. Am J Clin Nutr. 2007;85(5):1174-1184.
Forchielli ML, Bersani G, Tala S, et al. The spectrum of plant and animal sterols in different oil derived intravenous emulsions. Lipids. 2010;45(1):63-71.
Clayton PT, Bowron A, Mills KA, et al. Phytosterolemia in children with parenteral nutrition-associated cholestatic liver disease. Gastroenterology. 1993;105(6):1806-1813.
Smit JJ, Schinkel AH, Oude Elferink RP, et al. Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell. 1993;75(3):451-462.
Trauner M, Meier PJ, Boyer JL. Molecular pathogenesis of cholestasis. N Engl J Med. 1998;339(17):1217-1227.
Sinal CJ, Tohkin M, Miyata M, et al. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell. 2000;102(6):731-744.
Liu Y, Binz J, Numerick MJ, et al. Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis. J Clin Invest. 2003;112(11):1678-1687.
Carter BA, Taylor OA, Prendergast DR, et al. Stigmasterol, a soy lipid-derived phytosterol, is an antagonist of the bile acid nuclear receptor FXR. Pediatr Res. 2007;62(3):301-306.
Kurvinen A, Nissinen MJ, Gylling H, et al. Effects of long-term parenteral nutrition on serum lipids, plant sterols, cholesterol metabolism, and liver histology in pediatric intestinal failure. J Pediatr Gastroenterol Nutr. 2011;53(4):440-446.
Kurvinen A, Nissinen MJ, Andersson S, et al. Parenteral plant sterols and intestinal failure-associated liver disease in neonates. J Pediatr Gastroenterol Nutr. 2012;54(6):803-811.
El Kasmi KC, Anderson AL, Devereaux MW, et al. Phytosterols promote liver injury and Kupffer cell activation in parenteral nutrition-associated liver disease. Sci Transl Med. 2013;5(6):206ra137.
Mutanen A, Nissinen MJ, Lohi J, Heikkilä P, Gylling H, Pakarinen MP. Serum plant sterols, cholestanol, and cholesterol precursors associate with histological liver injury in pediatric onset intestinal failure. Am J Clin Nutr. 2014;100(4):1085-1094.
Hukkinen M, Mutanen A, Nissinen M, Merras-Salmio L, Gylling H, Pakarinen MP. Parenteral plant sterols accumulate in the liver reflecting their increased serum levels and portal inflammation in children with intestinal failure. J Parenter Enteral Nutr. 2017;41(6):1014-1022.
Isaac DM, Alzaben AS, Mazurac VC, et al. Mixed lipid, fish oil, and soybean oil parenteral lipids impact cholestasis, hepatic phytosterol, and lipid composition. J Pediatr Gastroenterol Nutr. 2019;68(6):861-867.
Rollins MD, Ward RM, Jackson WD, et al. Effect of decreased parenteral soybean lipid emulsion on hepatic function in infants at risk for parenteral nutrition-associated liver disease: a pilot study. J Pediatr Surg. 2013;48(6):1348-1356.
Sanchez SE, Braun LP, Mercer LD, et al. The effect of lipid restriction on the prevention of parenteral nutrition-associated cholestasis in surgical infants. J Pediatr Surg. 2013;48(3):573-578.
Ganousse-Mazeron S, Lacaille F, Colomb-Jung V, et al. Assessment and outcome of children with intestinal failure referred for intestinal transplantation. Clin Nutr. 2015;34(3):428-435.
Gura KM, Duggan CP, Collier SB, et al. Reversal of parenteral nutrition-associated liver disease in two infants with short bowel syndrome using parenteral fish oil: implications for future management. Pediatrics. 2006;118(1):e197-e201.
Gura KM, Lee S, Valim C, et al. Safety and efficacy of a fish oil-based fat emulsion in the treatment of parenteral nutrition-associated liver disease. Pediatrics. 2008;121(3):e678-e686.
Puder M, Valim C, Meisel JC, et al. Parenteral fish oil improves outcomes in patients with parenteral nutrition-associated liver injury. Ann Surg. 2009;250(3):395-402.
Diamond IR, Sterescu A, Pencharz PB, Kim JH, Wales PW. Changing the paradigm: omegaven for the treatment of liver failure in pediatric short bowel syndrome. J Pediatr Gastroenterol Nutr. 2009;48(2):209-215.
Goulet O, Antebi H, Wolf C, et al. A new intravenous fat emulsion containing soybean oil, medium-chain triglycerides, olive oil, and fish oil: a single-center, double-blind randomized study on efficacy and safety in pediatric patients receiving home parenteral nutrition. J Parenter Enteral Nutr. 2010;34(5):485-495.
Le HD, De Meijer VE, Zurakowski D, et al. Parenteral fish oil as monotherapy improves lipid profiles in children with parenteral nutrition-associated liver disease. J Parenter Enteral Nutr. 2010;34(5):477-484.
Muhammed R, Bremner R, Protheroe S, et al. Resolution of parenteral nutrition-associated jaundice on changing from a soybean oil emulsion to a complex mixed-lipid emulsion. J Pediatr Gastroenterol Nutr. 2012;54(6):797-802.
Premkumar MH, Carter BA, Hawthorne KM, King K, Abrams SA. High rates of resolution of cholestasis in parenteral nutrition-associated liver disease with fish oil-based lipid emulsion monotherapy. J Pediatr. 2012;162(4):793-798.e1.
Calkins KL, Dunn JC, Shew SB, et al. Pediatric intestinal failure-associated liver disease is reversed with 6 months of intravenous fish oil. J Parenter Enteral Nutr. 2014;38(6):682-692.
Lam HS, Tam YH, Poon TC, et al. A double-blind randomised controlled trial of fish oil-based versus soy-based lipid preparations in the treatment of infants with parenteral nutrition-associated cholestasis. Neonatology. 2014;105(4):290-296.
Pichler J, Simchowitz V, Macdonald S, Hill S. Comparison of liver function with two new/mixed intravenous lipid emulsions in children with intestinal failure. Eur J Clin Nutr. 2014;68(10):1161-1167.
Diamond IR, Grant RC, Pencharz PB, et al. Preventing the progression of intestinal failure-associated liver disease in infants using a composite lipid emulsion: a pilot randomized controlled trial of SMOF lipid. J Parenter Enteral Nutr. 2017;41(5):866-877.
Zhang T, Wang N, Yan W, et al. Effect of a fish oil-based lipid emulsion on intestinal failure-associated liver disease in children. Eur J Clin Nutr. 2018;72(10):1364-1372.
Calkins KL, DeBarber A, Steiner RD, et al. Intravenous fish oil and pediatric intestinal failure-associated liver disease: changes in plasma phytosterols, cytokines, and bile acids and erythrocyte fatty acids. J Parenter Enteral Nutr. 2018;42(3):633-641.
Lam CKL, Church PC, Haliburton C, et al. Long-term exposure of children to a mixed lipid emulsion is less hepatotoxic than soybean-based lipid emulsion. J Pediatr Gastroenterol Nutr. 2018;66(3):501-504.
Wang C, Venick RS, Shew SB, et al. Long-term outcomes in children with intestinal failure-associated liver disease treated with 6 months of intravenous fish oil followed by resumption of intravenous soybean oil. J Parenter Enteral Nutr. 2019;43(6):708-716.
de Meijer VE, Le HD, Meisel JA, Gura KM, Puder MJ. Parenteral fish oil as monotherapy prevents essential fatty acid deficiency in parenteral nutrition dependent infants. Pediatr Gastroenterol Nutr. 2010;50(2):212-218.
Nandivada P, Carlson SJ, Chang MI, Cowan E, Gura KM, Puder M. Treatment of parenteral nutrition-associated liver disease: the role of lipid emulsions. Adv Nutr. 2013;4(6):711-717.
Goulet O, Lambe C, Talbotec C, et al. Intravenous lipid emulsion containing 15% fish oil provides a new red blood cell fatty acids profile [abstract]. Transplantation. 2017;101(6S2):S73.
Seida JC, Mager DR, Hartling L, Vandermeer B, Turner JM. Parenteral ω-3 fatty acid lipid emulsions for children with intestinal failure and other conditions: a systematic review. J Parenter Enteral Nutr. 2013;37(1):44-55.